Education
About Us
Working with TipRanks
Follow Us
Hard to Treat Diseases (HTDS)
:HTDS
HTDS Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
HTDS FAQ
What was Hard to Treat Diseases’s price range in the past 12 months?
Currently, no data Available
What is Hard to Treat Diseases’s market cap?
Currently, no data Available
When is Hard to Treat Diseases’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Hard to Treat Diseases’s earnings last quarter?
Currently, no data Available
Is Hard to Treat Diseases overvalued?
According to Wall Street analysts Hard to Treat Diseases’s price is currently Overvalued.
Does Hard to Treat Diseases pay dividends?
Hard to Treat Diseases does not currently pay dividends.
What is Hard to Treat Diseases’s EPS estimate?
Hard to Treat Diseases’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Hard to Treat Diseases have?
Hard to Treat Diseases has 5,482,337,000 shares outstanding.
What happened to Hard to Treat Diseases’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Hard to Treat Diseases?
Currently, no hedge funds are holding shares in HTDS
Company Description
Hard to Treat Diseases
Hard to Treat Diseases Inc. manufactures, supplies, and exports biopharmaceuticals and vaccines in China and internationally. The company offers biologicals, including reteplase (rPA), mycobacterium vaccae, acutobin urinary kallidinogenase, ulinastatin, and cerebroprotein hydrolysate for injection; chemicals, such as cobratide injection, entecavir capsule, HES, dasatinib tablets, thymosin a1 for injection, imipenem and cilastatin sodium for injection, and meropenem for injection; and vaccines, which include rabies vaccine, ACYW135 meningococcal vaccine, influenza vaccine, Hepatitis A, and varicella vaccine. It markets its products through a sales network that focuses on South Asia, South-east Asia, Central and South America, and the Middle East. Hard to Treat Diseases Inc. was founded in 2009 and is based in Shenzhen, China.
Biodexa Pharmaceuticals
―
Salarius Pharmaceuticals
―
Processa Pharmaceuticals
―
GRI Bio
―
Onconetix
―